|
zoledronate
zoledronate
information and resources from the National Cancer Institute
zoledronate
The brand name for zoledronic acid, a bisphosphonic imidazol compound which inhibits osteoclastic bone resorption. Although its mechanisms of action is yet to be fully characterized, zoledronic acid appears to directly inhibit osteoclast function and trigger osteoclast apoptotic cell death, thereby decreasing the osteoclast stimulation and bone calcium loss induced by various tumor-associated cytokines. zoledronate
The brand name for zoledronic acid, a bisphosphonic imidazol compound which inhibits osteoclastic bone resorption. Although its mechanisms of action is yet to be fully characterized, zoledronic acid appears to directly inhibit osteoclast function and trigger osteoclast apoptotic cell death, thereby decreasing the osteoclast stimulation and bone calcium loss induced by various tumor-associated cytokines.
Zometa
the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy
Novartis Feb 22 2002
|
|
|
|
|
|
zoledronate
-->
|
